The rate of major molecular response at 24 months was 45% (35% for imatinib-resistant patients and 74% for imatinib-intolerant patients).
Oluline molekulaarne ravivastus oli 24 kuul 45% (35% imatiniibile resistentsetel patsientidel ja 74% imatiniibi mittetalunud patsientidel).